For example, the causal gene duplication defect for the most common form of CMT (PMP22) was identified in 19919,10 and confirmation that the resulting elevated gene dosage is responsible for the pathology of the disease was established in 1993, yet the first high throughput screen (HTS) to search for a small molecule therapeutic was not published until 201211. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease.